XTAE
BARI
Market cap351mUSD
Jun 02, Last price
7,058.00ILS
Name
Panaxia Labs Israel Ltd
Chart & Performance
P/E
—
P/S
53.95
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-55.07%
Rev. gr., 5y
179.52%
Revenues
20m
-50.31%
Net income
-13m
L-69.02%
CFO
-563k
L-93.75%
Dividend
Jun 03, 2012107.388 ILS/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Panaxia Labs Israel Ltd (PNAX.TA) is a pharmaceutical company that provides specialized medical solutions to healthcare professionals and patients, operating both within Israel and across global markets. The firm's primary offerings include medicinal-grade, non-combustible cannabis formulations. These are available in various delivery methods, such as oral, rapidly dissolving, and sublingual tablets; ingestible oils; sublingual drops; solutions for inhalation; lozenges; topical preparations; suppositories; and ethanol-based cannabis extracts. These products are distributed under several brand names, including NAXIVA PANAXOL, NAXIVA-PANAXOL-ONKO, PANAXIR SENSE, PANAXIR, Axiban, Tikva, Ultra Health, and Salus. Established in 2005, the company maintains its headquarters in Lod, Israel.
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||